Zhang Jin-Wei
Medical School, University of Exeter, Exeter EX4 4PS, United Kingdom.
World J Clin Cases. 2024 Oct 6;12(28):6247-6249. doi: 10.12998/wjcc.v12.i28.6247.
This editorial comments on the study by Lei investigating the efficacy of early treatment with pirfenidone on the lung function of patients with idiopathic pulmonary fibrosis (IPF) published. This study evaluates the efficacy of early treatment with pirfenidone on lung function in patients with IPF. The early and advanced stages of IPF are defined, highlighting the drug's benefits. While prior research indicates pirfenidone's effectiveness in advanced IPF, this study focuses on its advantages in early stages. The study emphasizes the importance of computed tomography imaging alongside biochemical data and lung function tests for a comprehensive analysis of symptom relief. Results show that early intervention with pirfenidone significantly reduces disease progression and preserves lung function, underscoring its potential as a critical treatment strategy in early IPF.
这篇社论评论了雷关于吡非尼酮早期治疗对特发性肺纤维化（IPF）患者肺功能影响的研究。该研究评估了吡非尼酮早期治疗对IPF患者肺功能的疗效。明确了IPF的早期和晚期阶段，突出了该药物的益处。虽然先前的研究表明吡非尼酮在晚期IPF中有效，但本研究重点关注其在早期阶段的优势。该研究强调了计算机断层扫描成像与生化数据和肺功能测试相结合对于全面分析症状缓解情况的重要性。结果表明，吡非尼酮的早期干预显著降低了疾病进展并保留了肺功能，突显了其作为早期IPF关键治疗策略的潜力。
